ABOUT IIRC
The IIRC will build on our strong transnational research and clinical programs and will enable us to:

- Grow research in basic immune mechanisms with translational endpoints
- Develop first-in-class immunotherapies
- Accelerate innovation through interdisciplinary, inter-divisional science

IIRC RESEARCH PROGRAMS
Through the IIRC we will advance interdivisional and interdisciplinary research focusing on the following:

- Cell Therapy (TCR/CAR)
- Transplant Immunology
- *Tumor Microenvironment, Immune Checkpoint & Regulation
- *Immunogenomics, Therapeutic Vaccines

* Research programs for development & faculty recruitment

December 2016

From the Director
On Monday December 12, we officially opened the Bezos Family Immunotherapy Clinic at SCCA. This clinic is first-in-class for cellular therapy, described by Juno Therapeutics CSO Hy Levitsky as “enabling an iterative series of small clinical trials with biological endpoints, focusing on therapeutic optimization to take forward into conventional efficacy studies.” Like the bone marrow transplant program before us, we now have a home for the committed team of doctors, nurses, researchers and support staff needed to define the scientific principles for using immunotherapy to cure cancer. David Maloney serves as the first Medical Director for Cellular Immunotherapy and the Immunotherapy Clinic. We are incredibly grateful to our partners, the Bezos Family, for their decade-long dedication to our program.

I am pleased to serve as the first Director of the Immunotherapy Integrated Research Center (IIRC). The vision for this center is to unite research in immunotherapy across Divisions and Programs, broaden the scientific interest in immunotherapy, and to expand our efforts in fundamental, translational, and clinical research. The IIRC will bring together faculty in areas of synergy as we strive to make discoveries and develop the next generation therapies for patients. As the first IRC at Fred Hutch, there is much work to be done. Areas of immediate focus are:

- Expanding the depth and breadth of immunotherapy research at Fred Hutch with strategic focus on tumor microenvironment/immune regulations, cancer genomics, and therapeutic vaccines in addition to current strengths
- Recruiting, retaining, and supporting faculty dedicated to immunotherapy
- Expanding partnerships between basic, translational, and clinical researchers

Lymphoma patient Stephanie Florence of Lewiston, Idaho performs the ceremonial ribbon cutting at the new Bezos Family Immunotherapy Clinic at the Fred Hutchinson Cancer Research Center on Dec. 12, 2016.
FROM THE DIRECTOR, CONTINUED

Just as moving a therapeutic from the lab to the clinic takes the persistence of a dedicated team, developing the IIRC will require similar tenacity and the contribution of a range of individuals. I have asked several people representing all five divisions to participate in an Internal Advisory Board, including:

- Fred Appelbaum, CRD
- Aude Chapuis, CRD
- Mac Cheever, CRD
- Bruce Clurman, CRC
- Philip Greenberg, UW/CRD
- David Maloney, CRD
- Oliver Press, CRD
- Jason Bielas, PHS
- Michael Boeckh, VIDD
- Roland Strong, Basic Sciences
- Niki Robinson, BDIR

We currently have 46 members in the IIRC, 22 of which are junior faculty, and have representation from all divisions. Dr. Marion Dorer is the IIRC Administrative Director, and Project Manager Sheila Charles and Admin Coordinator Jen Casserd provide administrative, project, and programmatic support for the IIRC.

---

**SHAREED RESOURCE**

**Experimental Histopathology**

Dr. Rob Pierce is the first IIRC recruit. Rob joined Fred Hutch in November as a Member in the Clinical Research Division and Scientific Director of Experimental Pathology. He has taken on responsibility for the scientific and medical oversight of the current Experimental Histopathology Core, which remains a critical component of Fred Hutch’s excellent shared resource infrastructure. Experimental Histopathology will remain true to its mission of providing high-quality and timely histopathology resources to all shared core users irrespective of divisional affiliation and relevance to immune-oncology. Rob will also build immunopathology capabilities to assist IIRC investigators in understanding mechanisms of immune subversion in the tumor microenvironment, including:

- Multispectral immunohistochemistry
- Correlated Nanostring or RNA-seq-based transcriptional analysis
- Histoculture of tumor and normal tissue as translational platform
- Development of new tissue-based technology

Please contact Rob Pierce at rpierce@fredhutch.org for more information.

---

**SHAREED RESOURCE**

**Biostatistical Support for IIRC Members**

The IIRC has arranged for Biostatistical support for IIRC members. Dr. Qian (Vicky) Wu is a newly recruited biostatistician who is interested in working with investigators on clinical trials and correlative and research studies. Vicky joined the Center this summer as an Assistant Member and has expertise and interests in:

- Precision medicine
- High dimensional data analysis (GWAS, ChIP-seq, RNA-seq, subgroup identification)
- Trial design
BIOSTATISTICAL SUPPORT FOR IIRC MEMBERS, CONTINUED

As of January, the IIRC will be supporting a Statistical Research Associate to work with Vicky and assist in the biostatistical needs for projects of the IIRC members. Over the next 1-2 years, it will be incumbent upon investigators to write biostatistical support into grants and contracts for the long-term support of this service. Please contact Vicky Wu at qwu@fredhutch.org about collaborations.

PROGRAMS AND EVENTS

IIRC Faculty Retreat – January 11th at MOHAI

Join us for the first IIRC Faculty Retreat on January 11th at the Museum of History and Industry (MOHAI), conveniently located at the southern tip of Lake Union – about a 5-minute walk from Fred Hutch. The full-day program will feature presentations by immunotherapy researchers, interactive discussions, and a cocktail reception. For more information, please contact Sheila Charles, scharles@fredhutch.org.

Click here to visit our website and view the full agenda.

A – MOHAI main entrance
B – North Lot: ADA Parking and valet drop-off
C – Metered parking and street car stop
D – Metered parking Lot
E – AGC parking